Philadelphia Business Journal - “Teva Assembles Brainiacs to Study Mystery Disease”

 – July 29, 2013 /Press Release/  –– 

Teva Pharmaceutical Industries Ltd. has formed global scientific research collaboration to learn more about, and develop new therapeutic approaches for, Huntington's disease. The focus of the program will be on the interaction between laquinimod, a neuroprotective agent being studies as a potential multiple sclerosis treatment, and various molecular pathways operative in Huntington disease. Gareth John, MD, of the Icahn School of Medicine at Mount Sinai will be one of the included researchers. 
Learn more